# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth Barrett Browning (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI026-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clementine Haverford-Asante, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review: final cultures, vitamin D, mood, safety, and the opioid dose. **S**

## History of present illness

Ms. Barrett Browning returns three months after diagnosis. Her sputum is down to about a tablespoon a day and she has seen no blood since the first month. She had three nights of restlessness and lighter sleep after the first morphine step and then settled; she has taken no extra doses. She has had twelve grief therapy sessions and has begun to write about her brother, which she could not do before. She has gained almost 2 kg. She would like to take the next small step down. **S**

| Element | Detail |
|---|---|
| Lungs | About a tablespoon of sputum a day; no blood; no exacerbation |
| Opioid step | 9 mg twice daily for eight weeks; three restless nights, then settled |
| Grief therapy | Twelve sessions |
| Weight | 43.3 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy better |
| Respiratory | Positive | Morning cough with a little sputum; no blood |
| Gastrointestinal | Negative | Stools regular; appetite better |
| Psychiatric | Negative | Mood lighter; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 **S**
- Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily **S**
- Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day) **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 43.3 kg; BMI 17.6 kg/m². All vital signs are synthetic.

25-hydroxyvitamin D: 34 ng/mL; PHQ-9: 7; GAD-7: 5. All results are synthetic.

## Change since baseline

- 25-hydroxyvitamin D: 15 ng/mL (low) at baseline, 34 ng/mL at this visit **S**
- PHQ-9: 12 at baseline, 7 at this visit **S**
- GAD-7: 9 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 43.3 kg |
| Respiratory | A few crackles at the left base only |
| Neurological | Not drowsy; no tremor, sweating or yawning |
| Psychiatric | Brighter; speaks of her brother with sadness but without being overwhelmed; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bronchiectasis** (J47.9). Stable on airway clearance. Mycobacterial cultures are final and negative at eight weeks, for both tuberculosis and nontuberculous mycobacteria. The sputum culture sent last week grew normal flora only. **S**
   - Continue airway clearance twice daily.
   - Pneumococcal vaccine at the preventive visit next month.
   - Spirometry and mycobacterial culture at one year.
2. **Long-term opioid therapy: second step** (Z79.891). The first step was well tolerated. She chooses a second small step. **S**
   - Morphine solution 4 mL (8 mg) twice daily from today.
   - Hold this dose at least four weeks, longer if she wishes.
   - Prescription monitoring program checked.
3. **Prolonged grief disorder** (F43.81). PHQ-9 7 and GAD-7 5, improving after twelve sessions; no suicidal ideation. **S**
   - Finish the sixteen sessions.
   - Safety plan reviewed.
4. **Vitamin D deficiency, resolved** (E55.9). 25-hydroxyvitamin D 34 ng/mL after twelve weeks. **S**
   - Vitamin D3 1000 to 2000 units daily long term; recheck yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Completed today | Final at eight weeks: no growth of Mycobacterium tuberculosis or nontuberculous mycobacteria; next yearly |
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Normal flora only |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily; sputum about a tablespoon a day |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | None since diagnosis |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | None since the first month |
| Imaging | Spirometry and Bronchiectasis Severity Index | At diagnosis, then yearly | Up to date | Next at one year |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; sleep and function better; second step chosen |
| Medication safety | Dose reduction at her request: withdrawal symptoms and sleep | Four weeks after each step | Completed today | Three restless nights after the first step, then settled; no extra doses |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Urine drug test | At the start of review, then at least yearly | Up to date | Consistent with morphine only at intake; next at one year |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone in date at home; no sedatives |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Completed today | 7, from 10; GAD-7 5 |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan current |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions | Completed today | Twelve sessions attended |
| Laboratory | 25-hydroxyvitamin D | Twelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID) | Completed today | 34 ng/mL; next yearly |
| Examination | Weight and BMI | Every visit | Completed today | 43.3 kg, BMI 17.6 |

## Goal progress

- Tuberculosis excluded and a diagnosis for the cough within two weeks. Outcome by 2026-03-23: Smears, NAAT and IGRA negative within a week; bronchiectasis diagnosed by CT at one week. **S**
- Airway clearance twice daily, with less sputum and no blood in it, by three months. Outcome by 2026-06-15: Airway clearance twice daily; sputum down from about four to one tablespoon a day; no blood since the first month. **S**
- Safe opioid therapy: naloxone at home, no overdose or sedation, and any dose change only by her choice. In progress; target 2026-10-19. **S**
- Response of grief and depressive symptoms (PHQ-9 down by at least half) by six months. In progress; target 2026-10-19. **S**
- Weight up toward a BMI of 18.5 (45.6 kg) by seven months. In progress; target 2026-10-19. **S**
- Vitamin D above 30 ng/mL by twelve weeks. Outcome by 2026-06-15: 34 ng/mL. **S**

## Medication changes

- Started: Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day) **S**

## Guideline basis

- British Thoracic Society Guideline for Bronchiectasis in Adults (2019), British Thoracic Society (Thorax 2019;74 Suppl 1:1-69)
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), ATS, IDSA and CDC (Clin Infect Dis 2017;64(2):111-115)
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020), ATS, ERS, ESCMID and IDSA (Clin Infect Dis 2020;71(4):e1-e36)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016), JAMA Psychiatry 2016;73(7):685-694
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026), Aether Forge

## Follow-up

- Preventive visit next month. Seven-month review in the autumn with the PHQ-9, sputum culture, the influenza vaccine and the next opioid decision. Emergency care for more than a few teaspoons of blood. **S**
- Next scheduled visit 2026-07-13: periodic adult preventive visit. **S**
